DRIO
DarioHealth·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DRIO
Dariohealth Corp.
A leading developer of medical devices and solutions to monitor blood glucose using smart phones
Healthcare Equipment and Supplies
08/11/2011
03/04/2016
NASDAQ Stock Exchange
196
12-31
Common stock
322 W. 57th St., New York, New York 10011
--
DarioHealth Corp., founded on August 11, 2011, is a Delaware corporation. Originally a direct-to-consumer digital therapy company, the company first solved the problem of how to attract users and support behavioral change to improve clinical outcomes of diabetes. Beginning in 2020, the company has implemented a strategy to transform its business model, adopting a business-to-consumer approach, leveraging the advantages of the consumer solutions platform to provide business growth opportunities in traditional health business channels by selling products to health plans and employers.
Earnings Call
Company Financials
EPS
DRIO has released its 2025 Q3 earnings. EPS was reported at -2.96, versus the expected -2.42, missing expectations. The chart below visualizes how DRIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DRIO has released its 2025 Q3 earnings report, with revenue of 5.01M, reflecting a YoY change of -32.55%, and net profit of -10.47M, showing a YoY change of 15.12%. The Sankey diagram below clearly presents DRIO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available


